Venture capitalist Tim Draper warned that businesses could eventually reject dollars in favor of bitcoin, leading to bank runs as demand for fiat currencies declines. He reiterated his $250,000 bitcoin price forecast, now expected by October 2027, and urged companies to hold bitcoin reserves. Draper highlighted growing bitcoin payment adoption by platforms like Square and restaurants, suggesting a future where bitcoin is the primary currency. He cautioned that those unprepared with bitcoin could be left behind in this financial shift.
Tim Draper's views on Bitcoin come as most major cryptocurrencies on Pluang fell today, with only 4 out of 50 rising as of Oct 30, 2026 09:01 WIB. Among notable movers, YFI dropped 10.43% to Rp33.836.243 with a typical hold time of 94 days and 100% buy order activity, contrasting with SNX which fell 10.39% to Rp3.227 and saw 100% sell orders over a 71-day hold. ENJ also declined 9.95% to Rp414, holding a 94% buy order activity and a 105-day typical hold time.
As 2027 nears, cancer research is making strides worldwide with AI aiding treatment development, precision medicine tailoring therapies to tumor biology, and new clinical trials showing improved survival. Initiatives like Anthropic's support for chil...
FirstCash Holdings, Inc. shares fell 14.75% on October 22, 2026, after the company reported a 28% year-over-year decline in operating income for its American First Finance segment and a 15% drop in lease and loan originations for Q3. The decline was ...
First Hawaiian, Inc. and TriCo Bancshares have received shareholder approval for First Hawaiian's acquisition of TriCo, pending customary closing conditions. This merger aims to combine their banking services and expand their capacity to serve custom...
Intel's shares dropped 22% in after-hours trading following its fourth-quarter revenue forecast of $15 billion to $16 billion, which fell short of the $17.1 billion market expectation by $1.1 billion to $2.1 billion. A large long position on Intel st...
Aspen Neuroscience, a biotech company focused on regenerative medicine for Parkinson's disease, priced its initial public offering at $15 per share, offering 9.375 million shares to raise approximately $140.6 million. The company plans to use the pro...
